• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sorafenib maintenance therapy after allogenic stem cell transplantation reduces relapse rate in FLT3-ITD acute myeloid leukemia

byMichael PratteandArnav Agarwal, MD
October 17, 2020
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Sorafenib maintenance therapy following allogenic stem cell transplantation in FLT3-ITD acute myeloid leukemia was associated with significantly lower rates of cancer relapse at 1 year post-transplantation.

2. Sorafenib maintenance therapy was well-tolerated and had a similar safety profile to a non-maintenance therapy control.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with the FLT3-ITD mutation in acute myeloid leukemia (AML) have a particular poor prognosis. Several studies have shown maintenance therapy post-transplantation with the multikinase inhibitor sorafenib may reduce risk of relapse and improve survival. In the absence of prior randomized trial evidence, sorafenib was therefore recommended as maintenance therapy post-allogenic stem cell transplantation in this setting (evidence level B-II), yet it lacks data from randomized trials. This phase 3 open-label, randomized trial compared the use of sorafenib maintenance therapy after allogenic hematopoietic stem cell transplantation to a no-maintenance control. Overall, sorafenib maintenance was associated with a significantly lower rate of relapse at 1 year of follow-up post-transplantation. Sorafenib was also well-tolerated, with a similar safety profile to the control arm. Post-hoc multivariate analysis concluded that sorafenib maintenance therapy was the only factor that improved overall survival and leukemia-free survival. This study is important, as it is the first randomized phase 3 trial studying sorafenib maintenance therapy in the post-stem cell transplantation setting. Study limitations include lack of blinding, absence of a placebo arm, and duration of therapy only up to 6 months post-transplantation and not 1 year as is common in clinical practice. Nonetheless, trial results are promising regarding possible benefit with reasonable tolerability, and warrants consideration as a possible therapeutic option in this population.

Click to read the study in Lancet Oncology

Click to read an accompanying editorial in Lancet Oncology

RELATED REPORTS

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

Camrelizumab plus rivoceranib superior to sorafenib for treatment of unresectable hepatocellular carcinoma

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

Relevant reading: Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication

In-Depth [randomized controlled trial]: This open label randomized multicenter phase 3 trial was conducted in seven hospitals in China, and randomized 202 participants (100 to sorafenib, 102 to control). Patients aged 18 to 60 years with FLT3-ITD acute myeloid leukemia (AML) undergoing a first allogenic stem cell transplantation and achieving composite complete remission before and after transplantation with hematopoietic recovery within 60 days post-procedure were considered eligible. Half of included patients were female, and the average age was 35 years in both arms (interquartile range [IQR] 26 to 42 in sorafenib group, 26 to 43 in control group). The primary outcome was cumulative incidence of relapse 1-year post-transplant; secondary outcomes included overall and leukemia-free survival at 2 years, non-relapse mortality at 2 years, and adverse events until 210 days post-transplant. At 1-year post-transplant, the sorafenib group had significantly lower rates of relapse (7.0%, 95% confidence interval [CI] 3.1 to 13.1 vs. 24.5%, 95% CI 16.6 to 33.2; hazard ratio [HR] 0.25, 95% CI 0.11 to 0.57, p=0.001). Two-year overall survival was 82.1% (95% CI 72·6 to 88·5) and 68.0% (57.8 to 76.2) in sorafenib and control groups, respectively (HR 0.48, 95% CI 0.27 to 0.86; p=0.012). Leukemia-free survival at 2 years was 78.9% (95% CI 69.0 to 85.9) and 56.6% (46.1 to 65.8), respectively (HR 0.37, 95% CI 0.22 to 0.63; p<0·0001). Both sorafenib and control groups had high proportions of patients with at least one type of grade 3 or 4 adverse event (50% vs. 46%, respectively). Common adverse events included infections (25% vs. 24%), acute graft-versus-host disease (23% vs. 21%), chronic graft-versus-host disease (18% vs. 17%) and hematological toxicity (15% vs. 7%). Four patients in the sorafenib group and five in the control group died from adverse events. Based on these findings, sorafenib appears to be a reasonable maintenance therapy with a reduction in relapse rate and a comparable safety profile in patients with FLT3-ITD AML post-allogenic stem-cell transplantation.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute myeloid leukemia (AML)FLT3-ITD mutationsorafenib
Previous Post

Fifteen year quality of life outcomes in men with localized prostate cancer: population based Australian prospective study

Next Post

#VisualAbstract: Amoxicillin for the treatment of pneumonia with tachypnea in low resource settings

RelatedReports

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
AI Roundup

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

June 12, 2025
Prognostic nomograms predict survival after chemoembolization of hepatocellular carcinoma
Chronic Disease

Camrelizumab plus rivoceranib superior to sorafenib for treatment of unresectable hepatocellular carcinoma

October 11, 2023
Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy
Chronic Disease

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

May 13, 2022
Prophylactic platelet transfusions prevent bleeding in hematologic cancers
Oncology

Ivosidenib and azacitidine showed significant clinical benefit in newly diagnosed IDH1-mutated acute myeloid leukemia

May 2, 2022
Next Post
#VisualAbstract: Amoxicillin for the treatment of pneumonia with tachypnea in low resource settings

#VisualAbstract: Amoxicillin for the treatment of pneumonia with tachypnea in low resource settings

Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

2 Minute Medicine Rewind October 19, 2020

Quick Take: Analgesic efficacy and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study: randomised placebo-controlled trial

COVID-19 pandemic associated with decreased rates of institutional childbirth and increased neonatal mortality in Nepal

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
  • Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.